A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studies
2015 · BMC Cancer · 58 citations
https://doi.org/10.1186/s12885-015-1146-8
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
42
Papers
877
Citations
16
h-index
24
i10-index
John Morten is an academic researcher from AstraZeneca (United Kingdom). The author has contributed to research in topics: DNA Repair Mechanisms & Cardiac electrophysiology and arrhythmias & Ion channel regulation and function. The author has an h-index of 16, co-authored 36 publications.
https://doi.org/10.1186/s12885-015-1146-8
https://doi.org/10.1128/mcb.6.6.2223-2232.1986
Click to start Chat